BIOMAT Database Logo BIOMAT Database Logo

The effect of ouabain on pressor responses to infused noradrenaline in patients with essential hypertension. 1988

M Nishimura, and K Kikuchi, and K Aoki, and A Nozawa, and C Honma, and H Kobayakawa, and M Yamamoto, and M Shimazaki, and C Kudoh, and T Sakamoto
2nd Department of Internal Medicine, Sapporo Medical College, Japan.

The relationship between changes in the pressor response to infused noradrenaline induced by intravenous injection of ouabain, an Na+,K+-ATPase inhibitor, and plasma renin activity and plasma ionized calcium was examined in 16 normotensive subjects and in 16 patients with essential hypertension. These patients were divided into 11 normal-renin and five low-renin essential hypertensives. The pressor response was significantly greater in low-renin hypertensives than in normotensives and normal-renin hypertensives. Following the injection of ouabain, the pressor response was significantly increased with no change in basal levels of blood pressure, plasma noradrenaline concentration, plasma calcium and plasma parathyroid hormone in both normotensives and essential hypertensives. The pressor response to noradrenaline was negatively correlated with levels of plasma noradrenaline and calcium after the injection of ouabain as well as before the injection in normotensives and essential hypertensives. The regression line between the pressor response and that of plasma noradrenaline or plasma calcium was significantly shifted towards a higher pressor response in normotensives, but not in essential hypertensives. The changes in the pressor response to noradrenaline induced by the injection of ouabain was significantly smaller in essential hypertensives, particularly in low-renin hypertensives, compared with normotensives. These results suggest that: (1) ouabain increases the pressor response to noradrenaline; (2) this increase is related to calcium metabolism; (3) endogenous Na+,K+-ATPase inhibitor(s) might be elevated in essential hypertensives; and (4) an increase in endogenous Na+,K+-ATPase inhibitor might, therefore contribute to an enhanced noradrenaline response in essential hypertensives, particularly in low-renin hypertensives.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D009638 Norepinephrine Precursor of epinephrine that is secreted by the ADRENAL MEDULLA and is a widespread central and autonomic neurotransmitter. Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers, and of the diffuse projection system in the brain that arises from the LOCUS CERULEUS. It is also found in plants and is used pharmacologically as a sympathomimetic. Levarterenol,Levonorepinephrine,Noradrenaline,Arterenol,Levonor,Levophed,Levophed Bitartrate,Noradrenaline Bitartrate,Noradrénaline tartrate renaudin,Norepinephrin d-Tartrate (1:1),Norepinephrine Bitartrate,Norepinephrine Hydrochloride,Norepinephrine Hydrochloride, (+)-Isomer,Norepinephrine Hydrochloride, (+,-)-Isomer,Norepinephrine d-Tartrate (1:1),Norepinephrine l-Tartrate (1:1),Norepinephrine l-Tartrate (1:1), (+,-)-Isomer,Norepinephrine l-Tartrate (1:1), Monohydrate,Norepinephrine l-Tartrate (1:1), Monohydrate, (+)-Isomer,Norepinephrine l-Tartrate (1:2),Norepinephrine l-Tartrate, (+)-Isomer,Norepinephrine, (+)-Isomer,Norepinephrine, (+,-)-Isomer
D010042 Ouabain A cardioactive glycoside consisting of rhamnose and ouabagenin, obtained from the seeds of Strophanthus gratus and other plants of the Apocynaceae; used like DIGITALIS. It is commonly used in cell biological studies as an inhibitor of the NA(+)-K(+)-EXCHANGING ATPASE. Acocantherin,G-Strophanthin,Acolongifloroside K,G Strophanthin
D012083 Renin A highly specific (Leu-Leu) endopeptidase that generates ANGIOTENSIN I from its precursor ANGIOTENSINOGEN, leading to a cascade of reactions which elevate BLOOD PRESSURE and increase sodium retention by the kidney in the RENIN-ANGIOTENSIN SYSTEM. The enzyme was formerly listed as EC 3.4.99.19. Angiotensin-Forming Enzyme,Angiotensinogenase,Big Renin,Cryorenin,Inactive Renin,Pre-Prorenin,Preprorenin,Prorenin,Angiotensin Forming Enzyme,Pre Prorenin,Renin, Big,Renin, Inactive
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000254 Sodium-Potassium-Exchanging ATPase An enzyme that catalyzes the active transport system of sodium and potassium ions across the cell wall. Sodium and potassium ions are closely coupled with membrane ATPase which undergoes phosphorylation and dephosphorylation, thereby providing energy for transport of these ions against concentration gradients. ATPase, Sodium, Potassium,Adenosinetriphosphatase, Sodium, Potassium,Na(+)-K(+)-Exchanging ATPase,Na(+)-K(+)-Transporting ATPase,Potassium Pump,Sodium Pump,Sodium, Potassium ATPase,Sodium, Potassium Adenosinetriphosphatase,Sodium-Potassium Pump,Adenosine Triphosphatase, Sodium, Potassium,Na(+) K(+)-Transporting ATPase,Sodium, Potassium Adenosine Triphosphatase,ATPase Sodium, Potassium,ATPase, Sodium-Potassium-Exchanging,Adenosinetriphosphatase Sodium, Potassium,Pump, Potassium,Pump, Sodium,Pump, Sodium-Potassium,Sodium Potassium Exchanging ATPase,Sodium Potassium Pump

Related Publications

M Nishimura, and K Kikuchi, and K Aoki, and A Nozawa, and C Honma, and H Kobayakawa, and M Yamamoto, and M Shimazaki, and C Kudoh, and T Sakamoto
Plasma noradrenaline concentration and pressor response to infused noradrenaline in patients with borderline hypertension, and mild or moderate essential hypertension.
February 1984, Japanese circulation journal,
M Nishimura, and K Kikuchi, and K Aoki, and A Nozawa, and C Honma, and H Kobayakawa, and M Yamamoto, and M Shimazaki, and C Kudoh, and T Sakamoto
[Vascular responses to noradrenaline in patients with essential hypertension].
April 1970, Japanese circulation journal,
M Nishimura, and K Kikuchi, and K Aoki, and A Nozawa, and C Honma, and H Kobayakawa, and M Yamamoto, and M Shimazaki, and C Kudoh, and T Sakamoto
PRESSOR RESPONSE IN ESSENTIAL HYPERTENSION. BLOOD PRESSURE RESPONSE TO NORADRENALINE IN THE PATIENT WITH ESSENTIAL HYPERTENSION.
September 1963, Japanese heart journal,
M Nishimura, and K Kikuchi, and K Aoki, and A Nozawa, and C Honma, and H Kobayakawa, and M Yamamoto, and M Shimazaki, and C Kudoh, and T Sakamoto
[Clinical studies on the etiology of essential hypertension. Pressor response to noradrenaline].
January 1965, Sapporo igaku zasshi. The Sapporo medical journal,
M Nishimura, and K Kikuchi, and K Aoki, and A Nozawa, and C Honma, and H Kobayakawa, and M Yamamoto, and M Shimazaki, and C Kudoh, and T Sakamoto
[Pathogenesis of essential hypertension. Plasma noradrenaline, plasma renin and pressor effects of noradrenaline and angiotensin in normotensive patients and patients with essential hypertension].
August 1979, Fortschritte der Medizin,
M Nishimura, and K Kikuchi, and K Aoki, and A Nozawa, and C Honma, and H Kobayakawa, and M Yamamoto, and M Shimazaki, and C Kudoh, and T Sakamoto
Plasma noradrenaline and the pressor action of exogenous noradrenaline in normotensive subjects and patients with essential hypertension.
December 1978, Clinical science and molecular medicine. Supplement,
M Nishimura, and K Kikuchi, and K Aoki, and A Nozawa, and C Honma, and H Kobayakawa, and M Yamamoto, and M Shimazaki, and C Kudoh, and T Sakamoto
Effect of propranolol on noradrenaline kinetics in patients with essential hypertension.
September 1981, British journal of clinical pharmacology,
M Nishimura, and K Kikuchi, and K Aoki, and A Nozawa, and C Honma, and H Kobayakawa, and M Yamamoto, and M Shimazaki, and C Kudoh, and T Sakamoto
[Pressor effects of noradrenaline and tyramine in normotensive subjects and patients with essential hypertension and renovascular hypertension].
December 1969, Minerva medica,
M Nishimura, and K Kikuchi, and K Aoki, and A Nozawa, and C Honma, and H Kobayakawa, and M Yamamoto, and M Shimazaki, and C Kudoh, and T Sakamoto
Consequences of impaired arterial baroreflexes in essential hypertension: effects on pressor responses, plasma noradrenaline and blood pressure variability.
July 1988, Journal of hypertension,
M Nishimura, and K Kikuchi, and K Aoki, and A Nozawa, and C Honma, and H Kobayakawa, and M Yamamoto, and M Shimazaki, and C Kudoh, and T Sakamoto
The effect of chronic captopril therapy on adrenergic receptors, plasma noradrenaline and the vascular responses to infused noradrenaline.
January 1987, European journal of clinical pharmacology,
Copied contents to your clipboard!